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Global burden of cardiovascular disease: a call for action
Cardiovascular disease (CVD) is the leading cause of morbidity 
and mortality worldwide. The last decade has attested to the rapid 
globalization of the consumer society, which has profoundly 
impacted lifestyles and cardiovascular (CV) risk factors at a global 
scale. The growth of poor eating habits, obesity, and hypertension 
are relentlessly contributing to the development of an epidemic 
of CVD, the consequences of which have had the highest toll 
on low and middle-income economies (LMIC). The immediate 
consequence of this socio-demographic shift had a landmark in 
2010 when the World Health Organization (WHO) reported more 
than 17 million deaths globally were attributed to CVD, over 80% 
of which occurred in LMIC [1]. Moreover, global CVD mortality 
estimates project more than 23.6 million CVD related deaths by 
2030 [2]. Ischaemic heart disease and cerebrovascular diseases, 
the most frequent CVDs, are major causes of disability resulting 
in 130 million disability-adjusted life years (DALYs) lost in 2010 
[1].
In parallel, high income countries, where accessibility to 
resources is high, are encountering what has been termed as 
the ‘CVD mortality paradox’ [3], which describes the inverse 
relationship between CVD mortality and cost. In the US, the 
death rate from CVD has fallen about 39 percent between 2001 
and 2012 [2] as well as in most European countries [4], yet the 
burden and risk factors remain alarmingly high and the costs of 
treating CVD in high income countries are staggering. Data from 
the Heart Disease and Stroke Statistics from 2015 showed that 
the annual direct and indirect cost of CVD and stroke in the US 
United States is an estimated $320.1 billion. This figure includes 
$195.6 billion in expenditures (direct costs, which include the 
cost of physicians and other professionals, hospital services, 
prescribed medications, and home health care, but not the cost of 
nursing home care) and $124.5 billion in lost future productivity 
attributed to premature CVD and stroke mortality in 2011 
(indirect costs) [2]. In other words, CVD and stroke accounted 
for 15% of total health expenditures in 2011, more than any major 
diagnostic group [5]. In Europe, the total cost of CVD is estimated 
at €196 billion a year, of which 54% is due to health care costs, 
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Cardiovascular risk modification in terms of comprehensive medical therapy (antithrombotic therapy, 
lipid-lowering therapy, antihypertensive medication) and lifestyle modification (healthy diet, regular 
exercise, weight loss, smoking cessation) is the cornerstone of secondary prevention. It is now clear 
that even in those undergoing PCI or bypass surgery, appropriate lifestyle modification and aggressive 
medical therapy are paramount for optimizing long-term outcomes. However, what has emerged from 
studies that examined the role of medical therapy in the context of coronary heart disease is that 
only ~50% of the patients in these studies are achieving target treatment goals for blood pressure, 
lipid and glycemic control. Non-adherence is thought to be a very large contributor to this problem; 
across all health-care categories, non-adherence is estimated to account for $290 billion of annual 
health-care expenditure in the United States and €1.25 billion in European Union, with poor adherence 
to CVD medication accounting for 9% of all European CVD events. Socioeconomic factors may have a 
role in patients’ discontinuing their medications, and a major initiative to combat this problem is the 
increasing focus on the polypill. The idea of combining numerous medications into a single tablet 
to reduce CV risk was first proposed more than a decade ago. This combined formulation not only 
significantly enhances patient convenience and adherence but also drives savings for the healthcare 
systems. Several randomized clinical trials have consistently demonstrated the effects of polypills 
on CV risk factors and adherence, and major trials are underway to study the effect on hard clinical 
outcomes.
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24% due to productivity losses and 22% due to informal care 
of people with CVD [4]. Health care costs represent €212 per 
capita per annum, which is around 9% of the total health care 
expenditure across the EU. The economic impact of CVD in LMICs 
has been estimated to reduce gross domestic product by up to 
6.77% [6], which has already been impairing economic growth 
in certain regions.
Optimizing secondary prevention in patients with CVD 
remains as a big unmet need worldwide. The causes of inade-
quate secondary prevention are multiple. First, lack of treatment 
adherence in patients is a serious problem that has been 
overlooked in recent decades. The problem is most apparent 
in patients with chronic diseases and has been reported in 
all countries studied, irrespective of the health care system, 
economic situation, and education level [7]. Levels of adherence 
in secondary prevention, irrespective of the assessment tool, 
have consistently been shown to be about 50% [8,9]. Together 
with the type of drug, one of the main reasons for treatment 
discontinuation is its complexity and, particularly, the number 
of doses (ie, pills, capsules) that the patient must take every 
day [10]. The problem is bigger in LMIC, where access to the 
healthcare system may be limited and medical attention deficient. 
Medication is frequently unavailable or too expensive, given that 
health care coverage in LMIC is practically nonexistent and drugs 
in the private sector are expensive. The WHO-PREMISE study 
found that in some LMICs fewer than 40% of acute myocardial 
infarction patients received ACEIs, and only 20% received statins 
[11]. The Prospective Urban Rural Epidemiological (PURE) study 
included individuals from rural and urban communities in 
countries at various stages of economic development in order 
to establish accessibility to CV pharmacotherapy. The study 
confirmed that adherence with drugs for secondary prevention 
in patients with established CVD was generally low and worst in 
the low-income countries; with over 80% receiving none of the 
effective drug treatments in South Asia [12]. Thus, any attempt 
to apply individualized medicine in those countries according to 
our standards is a pipe dream. Despite the efforts of healthcare 
authorities, professionals, and scientific bodies, the situation 
in developed countries is still far from ideal. In countries with 
adequate accessibility to treatment, there is a need to increase 
effectiveness, which demands improving treatment adherence.
Evolution of the polypill concept
Limitations on real world applicability of various public 
health strategies to influence dietary and physical habits 
make it unfeasible to have a significant impact in a reasonable 
timeframe (such as educational efforts, legislation, dietary 
recommendations, public health system infrastructure to meet 
preventive needs, etc.). Hence, the concept of the polypill was 
proposed as a simple, innovative and cost-effective public health 
strategy to influence accessibility to medications and adherence 
to treatment at a global scale. For some health professionals, 
the idea of a polypill for CV prevention is merely an interesting 
concept that is of limited usefulness and applicability. For 
others, however, the polypill could save thousands of lives if 
used in the proper context and with the correct indication. What 
is clear to most is that the global burden of CVD requires new, 
simple approaches to impede the growth of CVD by effectively 
improving quality of care.
The concept of the CV polypill is now more than a decade old. 
It was originally proposed in 2001 by a WHO and Wellcome Trust 
expert group [13] and subsequently specified as a combination of 
four drugs (beta-blocker, angiotensin converting enzyme [ACE] 
inhibitor, aspirin and a statin), which was estimated to reduce 
CVD events by 75% in people with clinical evidence of CVD 
[14]. Reservations about this CV prevention strategy certainly 
are multifactorial, but a decisive part has clearly been played 
by the original interpretations of the role of the polypill and 
its possible indications. In 2003, Wald and Law claimed that a 
polypill containing six components and administered to each 
individual older than 55 years, irrespectively of their risk factors 
status, would reduce the incidence of cardiovascular disease by 
more than 80% [15]. This “vaccination approach” found strong 
opposition among the scientific community because of the 
unknown consequences of medicalizing an entire population, 
the costs of potential adverse reactions, psychological effects 
in a healthy population, as well as the possibility of promoting 
unhealthy lifestyle habits. Without suitable clinical studies 
demonstrating its efficacy, this strategy is unlikely to gain 
the acceptance of health care professionals and regulating 
authorities.
Based on Wald and Law’s initial idea, various authors 
proposed a more selective use of polypills for primary prevention 
in individuals without CVD but high CV risk [16]. There is no 
definitive proof of the efficacy, safety, or cost-effectiveness of 
this approach, although its feasibility has been shown in several 
pilot studies [17,18]. Overall, the studies show that the use of a 
CV polypill significantly increases treatment adherence [19–21]. 
None of these studies had the power to detect differences in 
the rate of new coronary events. Therefore, the results of new 
studies, some currently underway, are required to confirm that 
the polypill can play a role in the primary prevention of coronary 
disease.
The use of a polypill strategy has been advocated for secon-
dary prevention in patients with CVD, particularly those who 
have already had a myocardial infarction [22]. This strategy may 
improve treatment accessibility and affordability in developing 
countries and increase treatment adherence, still poor in all 
socioeconomic levels, which increases subsequent event rates 
and health care costs. The main strengths of a polypill strategy 
are the significant beneficial impact on adherence, as shown 
in numerous randomized clinical trials [9,19–21], and cost-
effectiveness, where polypills have been shown to be cost 
saving for health care systems [23–27]. Therefore, polypill 
based strategies for optimizing CV prevention are attractive 
options both for LMIC and developed countries. In this context, 
the Fuster-CNIC-Ferrer polypill was developed as a response 
to the current challenging global scenario of CVD. It is a three-
component polypill, comprising aspirin, a statin and an ACE 
inhibitor, designed for secondary prevention in patients who 
have already suffered a CV event. This polypill was designed as 
a key element for a comprehensive public health program of CV 
prevention, which necessarily must include education of patients 
and physicians on health promotion and changes in lifestyle.
From conceptual debate to worldwide reality: clinical 
evidence supporting the use of a cardiovascular polypill as a 
public health strategy
Evidence is available on the efficacy, safety, tolerability, 
affordability and effect on adherence of polypills for the primary 
and secondary prevention of CVD. All CV polypills that have 
been developed before the Fuster-CNIC-Ferrer CV polypill have 
not achieved the regulatory requirements to be approved in any 
European country or in USA.
Primary prevention
Several pilot studies have demonstrated the feasibility of the 
polypill-based primary prevention strategy [28–31]. In summary, 
these randomized trials have shown that the combination 
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of several antihypertensive agents, a statin, and aspirin can 
substantially reduce blood pressure and lipid levels (Table 1). The 
pills were well tolerated and showed low rates of adverse effects 
and discontinuation. The trials have also shown high adherence 
rates, although most have studied for short duration.
Secondary prevention
The potential value of applying the polypill concept for 
secondary prevention has been recognized by different expert 
panels, including the WHO and the Combination Pharmacotherapy 
and Public Health Research Working Group who advocate 
carrying out research that provides further evidence on the use 
of a polypill in this area [32–34]. For secondary prevention, TIPS-
2 reported significant reductions in BP and LDL-C in patients with 
stable CVD or diabetes with the use of the combination drugs 
used in TIPS-1, that is a polypill containing 3 BP-lowering drugs 
(atenolol 50 mg, hydrochlorothiazide 12.5 mg, and ramipril 5 
mg), 20 mg of simvastatin, and 100 mg of aspirin. In total, 518 
individuals eligible for secondary prevention were randomly 
allocated to receive either a single polypill, or 2 capsules of the 
polypill plus K+ supplementation for 8 weeks. Compared with 
Table 1
Principal Clinical Trials using a CV Polypill
Trial/Sample Size/Principal 
Investigator(s)
Population Polypill Composition Outcomes Status
Primary prevention
Indian Polycap Study (TIPS)
n=2053
Yusuf S, Pais P
Men and women aged 40–80 years 
without CVD and with at least 1 CV 
risk factor in India
Aspirin 100 mg, simvastatin 
20 mg, ramipril 5 mg, 
hydrochlorothiazide 12.5 mg, 
atenolol 50 mg
Feasibility; effect 
on risk factor levels; 
safety and tolerability
Completed
Poly-Iran: Phase II Study of Heart 
Polypill Safety and Efficacy in Primary 
Prevention of CV Disease
n=475
Marshall T, Malekzadeh R, 
Malekzadeh F
Men and women aged 
50–80 years without indications or 
contraindications for aspirin, 
BP-lowering drugs, and statins in 
Iran
Aspirin 81 mg, 
hydrochlorothiazide 12.5 mg, 
enalapril 2.5 mg, 
atorvastatin 20
Effect on risk factor 
levels; safety and 
tolerability
Completed
Combination Therapy Trial 
n=200 
Furberg C, Mendis S, Soliman EZ.
Age >40 years without CVD and with 
estimated 10-year total CVD risk 
score >20% in Sri Lanka
Aspirin 75 mg, simvastatin 
10 mg, lisinopril 10 mg, 
hydrochlorothiazide 10 mg 
(Red Heart Pill 2b)
Effect on estimated 
10-year total CVD risk 
score
Completed
IMProving Adherence using 
Combination Therapy (IMPACT) 
n=497 
Rodgers A, Selak A.
Established CVD or 5-year risk ≥15% Aspirin 75 mg, simvastatin 
40 mg, and lisinopril 10 mg 
with either atenolol 50 mg or 
hydrochlorothiazide 12.5 mg
Effect on adherence to 
recommended drugs 
and mean change in 
blood pressure and 
LDL-chol at 12 months
Completed
Indian Polycap Trial (TIPS)-3 
n=5000 
Yusuf S, Pais P, Xavier D, Liu L.
Primary prevention with estimated 
yearly CVD event rate of >1% using 
the INTERHEART risk score in China 
and India
Polycap; dose to be chosen 
after completion of the 
TIPS-K trials
Major CVD events; 
neurocognitive 
function
Estimated study 
completion date: 
January 2019
Heart Outcomes Prevention Evaluation 
(HOPE)-3
n=12,500
Yusuf S, Lonn E
Primary prevention in men aged >55 
years and women aged >65 years 
with at least 1 CV risk factor and 
women aged >60 years with at least 
2 risk factors and with average BP 
and cholesterol levels in 22 countries
Rosuvastatin 10 mg, 
candesartan 16 mg/
hydrochlorothiazide 12.5 mg 
(2×2 factorial design)
Major CVD events; 
neurocognitive 
function; renal 
function
Estimated study 
completion date: 
March 2016
Secondary prevention
FOCUS Trial in Secondary Prevention
Phase 1: n=2000, Phase 2: n=800
Fuster V
Survivors of myocardial infarction in 
Spain and Latin American countries
Aspirin 100 mg, simvastatin 
40 mg, ramipril 2.5, 5, 10 mg 
(Trinomia)
Adherence; feasibility; 
effect on risk factor 
levels; safety and 
tolerability
Completed
Use of a Multidrug Pill In Reducing CV 
Events UMPIRE
n=2000
Thom SA, Rodgers A
Established CVD or high-risk primary 
prevention (5-year CVD risk of >15%) 
in India, Netherlands, UK
Aspirin 75 mg, atenolol 
50 mg, simvastatin 40 mg, 
lisinopril 10 mg (Red Heart 
Pill 1) or aspirin 75 mg, 
hydrochlorothiazide 12.5 mg, 
simvastatin 40 mg, lisinopril 
10 mg (Red Heart Pill 2)
Adherence; effect 
on risk factor levels; 
safety and tolerability; 
CVD events 
(secondary outcome)
Completed
Patel 
n=623
Established CVD or high risk primary 
prevention (5-year CVD risk of >15%) 
Australia
Aspirin 75 mg, simvastatin 
40 mg, lisinopril 10 mg and 
either atenolol 50 mg or 
hydrochlorothiazide 12.5 mg.
Adherence to 
medications, systolic 
blood pressure and 
total cholesterol.
Completed
SECURE Trial 
n=3200 
Fuster V, Castellano JM
Elderly population (>65 years) with a 
diagnosis of AMI
Trinomia (Aspirin 100, 
Ramipril 2.5, 5 or 10mg, 
Atorvastatin 40mg) 
Composite primary 
endpoint of 
cardiovascular 
death, nonfatal MI, 
nonfatal ischaemic 
stroke and urgent 
revascularization
Ongoing. 
Estimated study 
completion date: 
April 2020.
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the single dose, the double-dose, or full-dose, reduced systolic 
and diastolic BPs and LDL-C levels by an additional 2.8 mmHg, 
1.7 mmHg, and 6.6 mg/dl, respectively. Both doses were similarly 
well tolerated. The investigators anticipate that the full-dose 
regimen would reduce the risk of CHD by 75%, and of stroke by 
65% [35].
The Use of a Multidrug Pill In Reducing cardiovascular Events 
(UMPIRE) study was the first randomized trial designed to 
assess the long-term effect of a polypill strategy in improving 
patients’ adherence to medication in CV prevention [20]. This 
trial included 2,004 patients (88% with CVD) from 3 European 
countries and India. Two different polypill strategies were used 
at the physicians’ discretion: 75 mg aspirin, 10 mg lisinopril, 
40 mg simvastatin, and either 50 mg atenolol or 12.5 mg 
hydrochlorothiazide. At the end of the study (median follow-up 
15 months), adherence to medication in the polypill group was 
85%, compared with 60% in the standard-care group (p<0.001). 
BP and LDL-cholesterol levels were reduced with the polypill 
strategy to a greater extent than with standard care, but the 
differences were modest (2.6 mmHg and 4.2 mg/dl, respectively; 
p<0.001 for each). No significant differences were reported in the 
incidence of serious adverse effects between the groups.
The IMPACT trial evaluated 513 adults at high risk of CVD (with 
established CVD or 5-year risk of ≥15%), who were recommended 
for treatment with antiplatelet, statin, and 2 or more BP-
lowering drugs, and were randomized to continued usual care 
or to polypill treatment (with 2 possible approaches: aspirin 75 
mg, simvastatin 40 mg, and lisinopril 10 mg with either atenolol 
50 mg or hydrochlorothiazide 12.5 mg) and included 12 months’ 
follow-up. The investigators found that, in line with other 
studies, adherence to all 4 recommended drugs was greater 
among polypill than usual care participants at 12 months (81% vs 
46%; relative risk 1.75, 95% CI 1.52-2.03, p<0.001) [21].
Patel et al. recently published the results of an open-label, 
randomized trial involving 623 participants recruited in 
Australian general practices [36]. Participants had established 
CVD or an estimated five-year CVD risk of ≥15%, with indications 
for antiplatelet, statin and ≥2 blood pressure lowering drugs 
(‘combination treatment’) and were randomized to the ‘polypill-
based strategy’ received a polypill containing aspirin 75 mg, 
simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg 
or hydrochlorothiazide 12.5 mg. Participants randomized to 
‘usual care’ continued with separate medications and doses 
as prescribed by their physician. Primary outcomes were self-
reported adherence to medications, systolic blood pressure 
and total cholesterol. After a median of 18 months, patients 
randomized to the polypill presented a significantly higher 
adherence than those receiving usual care (70% vs 47%, p<0.001). 
The study found no significant differences in BP or LDL-C 
between both groups, possibly due to limited power of the study.
The FOCUS (Fixed Dose Combination Drug for Secondary 
Cardiovascular Prevention) study was the first to prove the 
benefits of a polypill strategy in secondary prevention. FOCUS 
was fully funded by the FP7 EC programme and consisted 
of a cross-sectional study (Phase 1) of 2118 post MI patients 
recruited in Argentina, Brazil, Italy, Paraguay, and Spain, aimed 
to elucidate factors that interfere with appropriate adherence 
to CV medications for secondary prevention after an AMI [37]. 
Additionally, 695 patients from phase 1 were randomized into 
a controlled clinical trial (Phase 2) to test the effect of Fuster-
CNIC-Ferrer CV polypill (a polypill containing aspirin 100 mg, 
simvastatin 40mg and ramipril 2.5, 5 or 10 mg) compared to 
the three drugs given separately on adherence, blood pressure 
(BP) and low density lipoprotein cholesterol (LDL-C), as well as 
safety and tolerability over a period of 9 months of follow-up. 
Primary end-point in phase 2 was adherence to the treatment 
measured at the final visit by the self-reported Morisky-Green 
Adherence Questionnaire (MAQ) and pill count (patients had to 
meet both criteria for adherence at the in-person visit in order 
to be considered adherent). The results of phase 1 showed a very 
low overall CV medication adherence of 45.5%. In a multivariable 
regression model, the risk of being non-adherent was associated 
with younger age, depression, being on a complex medication 
regimen, poorer health insurance coverage, and a lower level of 
social support, with consistent findings across countries. In Phase 
2, the polypill group showed improved adherence compared to 
the group receiving separate medications after 9 months follow 
up: 50.8% vs 41% (p=0.019; intention-to-treat population) and 
65.7% vs 55.7% (p=0.012; per protocol population) when using 
the primary endpoint, attending the final visit with MAQ and 
high pill count (80–110%) combined, to assess adherence. 
Adherence was also higher in the FDC group when measured by 
MAQ alone (68% vs. 59%, p=0.049). No treatment difference was 
found at follow-up in mean SBP (129.6 vs 128.6 mmHg), mean 
LDL-C levels (89.9 vs 91.7 mg/dL), serious adverse events (23 
[6.6%] vs. 21 [6%]) or death (1, 0.2% in each group). In consonance 
with other clinical trials, compared with the three drugs given 
separately, the use of a polypill strategy met the primary 
endpoint for adherence – self-reported and direct measured 
medication – for post-MI secondary prevention.
Ongoing clinical trials
Several large, ongoing studies are testing the ability of different 
polypills to reduce the occurrence of new CV events in real-world 
practice. TIPS-3, HOPE-3, Poly-Iran, and HOPE-4 are currently 
underway testing different combination pills against placebo. 
TIPS-3 will evaluate a preparation of the Polycap without aspirin 
(either the doses used in the first TIPS trial or enhanced doses 
based on results of the TIPS-K trial) versus placebo over 5 years 
in 5,000 individuals without CVD and with an estimated risk of 
major CVD of 1%/year in India and China. The ongoing HOPE-3 
trial is evaluating the concept of combined BP and cholesterol 
lowering medications in individuals without vascular disease 
and with average BP and cholesterol levels [38] in 22 countries in 
North and South America, Europe, Africa, Asia, and Australia and 
will soon complete enrollment of 12,500 individuals at moderate 
CV risk (men age 55 years, with women over 65 years with 1 
risk factor or women over 60 years with 2 risk factors). Patients 
are randomized to rosuvastatin 10 mg/day alone, a FDC of 
candesartan 16 mg/hydrochlorothiazide 12.5 mg/day alone, both, 
or neither (2×2 factorial design) for 5 years. The main outcomes 
will include major CVD events and changes in cognitive and 
renal function. The PolyIran study is seeking to determine the 
effects of a PolyPill (a FDC of 2 anti-hypertensive medications, 
atorvastatin, and aspirin) on primary and secondary prevention 
of CVD in Iranian adults older than 50 years [39]. This ambitious 
trial will divide the cohort in 3 arms: 3,500 randomly selected 
participants will receive the PolyPill once daily and minimal care 
(which consists of direct education and a pamphlet on CV risk 
reduction, biannual follow-ups and BP measurements); 3,500 
will receive only minimal care as described above; and 24,000 
participants will receive usual care (standard primary health care 
provided by the local physicians and Community Health Workers 
for the whole participants of Golestan Cohort study, consistent 
with the current Iranian Health Care System guidelines). The 
first and second arms will be compared via a 2-armed open-
labeled cluster RCT. The comparisons between arm 3 and the 
other 2 arms will be performed by means of a cohort multiple 
RCT design. Endpoints will include major CV events (death and 
hospitalization). HOPE-4 is a community cluster RCT that will 
evaluate an evidence-based program for CVD risk assessment, 
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treatment, and control involving simplified screening and 
treatment algorithms implemented by non-physician health 
workers coupled with lifestyle counseling and combination-
pill therapy [40]. The initial risk factor phase of the study will 
assess BP and cholesterol changes in Colombia and Malaysia (50 
communities), with plans to expand to 190 communities in 8 
countries to evaluate CVD events over 6 years.
The SECURE trial: comparing the efficacy of the Fuster-CNIC-
Ferrer CV Polypill vs. usual care in reducing major adverse 
cardiovascular events during secondary prevention.
The SECondary prevention of cardiovascUlaR disease in the 
Elderly (SECURE; EudraCT: 2015-002868-17; NCT0259612) 
study is a multicenter, international, randomized trial designed 
to evaluate the potential benefit of the Fuster-CNIC-Ferrer CV 
polypill, containing aspirin 100 mg, ramipril 2.5, 5 or 10 mgs 
and atorvastatin 40mg as a component of a cost-effective, 
globally available and comprehensive treatment strategy for 
secondary CV prevention. SECURE will enroll a total of 3206 
patients >65 years old within 8 weeks of a MI to compare the 
efficacy of this polypill in reducing major cardiovascular events 
(cardiovascular death, nonfatal MI, nonfatal ischemic stroke, 
and urgent revascularization) after a minimum of 2 years 
follow-up. The SECURE trial is funded by the European Union 
Horizon 2020 Research Support Program and coordinated by 
the Centro Nacional de Investigaciones Cardiovasculares (CNIC) 
in Spain. SECURE will start enrolling patients soon in in seven 
EU countries: Spain, Italy, Germany, France, Poland, Hungry and 
Czech Republic.
Polypill as a cost effective strategy in cardiovascular 
prevention
Considering the rising healthcare costs and their impact on 
the economy, it is critical to understand what the future might 
hold for CVD prevalence and cost. Currently, CVD is the leading 
cause of death and in the United States it already constitutes 
17% of overall national health expenditures. Projections show 
that between 2010 and 2030, real total direct medical costs of 
CVD are projected to triple, from $272.5 billion to 818.1 billion 
[5] (Figure 1). Part of the huge economic burden of CVD falls 
on the limited effectives of pharmacological treatment due to 
non-adherence to medication. In fact, direct and indirect costs 
of non-adherence to chronic treatments have been calculated 
between $100billion and $289billion annually in the US [41,42]. 
Non-adherence leads up to €1.25 billion in annually within 
the European Union with poor adherence to CVD medication 
accounting for 9% of all European CVD events [43]. Therefore, 
efforts to promote adherence are gathering worldwide attention 
from patients, providers, payers and regulators. A variety of 
interventions have been proposed, and range from blister 
packaging, case management, education with behavioral 
support, reminder calls, pharmacist-led, multicomponent inter-
ven tions, education with behavioral support, collaborative 
care, shared decision making. Not all interventions, however, 
provided evidence of benefit [44]. Complex interventions 
are generally believed to be more effective that simple ones, 
however little is known about potential trade-off between their 
increased costs and the cost saving that might be reduced from 
increased adherence. Moreover, complex interventions that may 
show effectiveness in a high income settings are generally non 
applicable to limited resource settings, where the burden of CVD 
is highest. For this reason, there has been a tremendous effect 
in analyzing the potential cost effectiveness of a CV polypill in 
various resource settings.
The cost-effectiveness of a polypill regimen for patients at 
high risk for CVD specifically in the setting of LMIC has also 
been tested. Gaziano et al. [26] performed a pharmacoeconomic 
study assessing 2 combination regimens, 1 for primary preven-
tion (which included aspirin, a calcium channel blocker, an 
angiotensin-converting enzyme inhibitor, and a statin) and 
another for secondary prevention (which included the same 
combination of drugs in group 1 but substituted a beta-blocker for 
the calcium channel blocker). The incremental cost-effectiveness 
ratio for the secondary regimen was between $306 and $388 per 
quality-adjusted life-year indicating a cost-effective intervention 
for patients with CVD in all developing regions, even in low-
income countries.
The results of a Markov-model-based cost-effectiveness 
analysis of the use of a polypill in the UK for secondary CVD 
prevention from improved adherence, have been recently 
published [27]. The model compared the use of Trinomia (Fuster-
CNIC-Ferrer polypill brand name containing 100 mg aspirin, 20 
mg atorvastatin and 2.5, 5, or 10 mg ramipril) with multiple 
monotherapy. Outcome measures were CV events prevented per 
1000 patients; cost per life-year gained; and cost per quality-
adjusted life-year (QALY) gained. The model estimates that for 
each 10% increase in adherence, an additional 6.7% fatal and 
non-fatal CV events can be prevented. In the base case, over 
10 years, the polypill would improve adherence by ~20% and 
thereby prevent 47 of 323 (15%) fatal and non-fatal CV events 
per 1000 patients compared with multiple monotherapy, with 
an incremental cost-effectiveness ratio (ICER) of £8200 per 
QALY gained. Probabilistic sensitivity analyses for the base-
case assumptions showed an 81.5% chance of the polypill being 
cost-effective at a willingness-to-pay threshold of £20,000 per 
QALY gained compared with multiple monotherapy. In scenario 
analyses that varied structural assumptions, ICERs ranged 
between cost saving and £21,430 per QALY gained. Based on 
this model, the polypill appears to be a cost-effective strategy 
to prevent fatal and non-fatal CV events in the UK. Furthermore, 
assuming that some 450,000 adults are at risk of MI, a 10 
percentage point uptake of the polypill could prevent 3260 CV 
events and 590 CV deaths over a decade [27].
Conclusions
The concept of a polypill, composed of a combination of 
medications that are known to effectively treat CVD, has been 
proposed as a simple, cost effective and innovative public health 
strategy to combat the CVD epidemic on a global scale. Several 
studies have shown the polypill to be well tolerated and superior 
in terms of adherence to standard of care.
Fig. 1. Projection of rise in cost of treating CVD in the US (in billions US) [5].
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Perhaps the best evidence for the polypill concept is in 
secondary prevention of CVD where its use has the potential to 
close the treatment gap that exists. Large CV clinical trials, such 
as FREEDOM, BARI-2D, and COURAGE have demonstrated that 
current treatment strategies for secondary prevention are not 
effectively improving the risk profiles of patients with CVD [45]. 
Also, large epidemiological studies have shown CVD therapy 
to vary across socioeconomic levels with the worst outcomes 
in LMICs [12]. Polypills have emerged as a way to bridge this 
treatment gap through simplifying treatment algorithms, 
improving patient adherence, improving accessibility, and 
reducing CV events and associated costs. The World Health 
Organization, citing positive study results, has recognized the 
polypill concept as a potential to bridge the treatment gap and 
named it a “best buy for cardiovascular disease prevention and 
control” in the setting of secondary prevention (post-MI and 
stroke). This has led to regulatory approval of the Fuster-CNIC-
Ferrer CV Polypill in more than 20 countries to date and its 
commercialization in 8 countries in Mexico, Central America, 
South America and Europe under the brands of Trinomia® and 
Sincronium®.
The results of various trials under way (SECURE, TIPS-3, and 
HOPE-4) designed to show actual reductions in morbimortality 
will provide the ultimate evidence for the global implementation 
of this cardiovascular prevention strategy.
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